<DOC>
	<DOCNO>NCT00294541</DOCNO>
	<brief_summary>This trial follow-up companion study Protocol ICA-17043-10 , Phase III , multi-center , efficacy safety study ICA-17043 . This open-label extension study collect safety data use ICA-17043 subject sickle cell disease ( SCD ) ( e.g. , HbSS , HbSC , HbSb0-thalassemia , HbSb+-thalassemia subject ) . All subject successfully complete ICA-17043-10 , deem appropriate study Investigator appropriate consent subject give , enroll ICA-17043-12 study ( Study 12 ) . Only patient participate ICA-17043-10 eligible open label study</brief_summary>
	<brief_title>A Study Evaluating Long-Term Safety ICA-17043 Sickle Cell Disease Patients With Without Hydroxyurea Therapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Successfully complete Study ICA1704310 Discontinued Study 10 12 follow DMC recommendation he/she HU , since stable dose HU least 3 month prior Day 1 Male , female capable become pregnant use appropriate birth control Has willingly give write informed consent participate study The subject , female , positive urine pregnancy test Day 1 ( enter study ) The subject presently unsuitable participation longterm study</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>sickle cell anemia</keyword>
</DOC>